Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 4/20 | 0.50 |
| ▸ | NPC1 | O15118 | 3/20 | 0.50 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | HTR7 | P34969 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | PLOD2 | O00469 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | CES2 | O00748 | 1/20 | 0.43 |
| ▸ | CES1 | P23141 | 1/20 | 0.43 |
| ▸ | SRD5A2 | P31213 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1879336 | 0.90 | NPC1 (0.55) | RAB9ANPC1LMNAHTTL3MBTL1 | |
| SCHEMBL6201900 | 0.90 | RAB9A (0.59) | RAB9ANPC1PTPN1LMNAHTT | |
| SCHEMBL16367718 | 0.85 | SRD5A2 (0.59) | RAB9ANPC1PTPN1LMNAHTT | |
| SCHEMBL7167952 | 0.83 | SRD5A2 (0.62) | RAB9ANPC1PTPN1LMNAHTT | |
| SCHEMBL5724883 | 0.83 | RAB9A (0.68) | RAB9ANPC1PTPN1LMNAHTT | |
| SCHEMBL6158144 | 0.82 | NPC1 (0.56) | RAB9ANPC1PTPN1L3MBTL1HTR7 | |
| SCHEMBL10102425 | 0.81 | RAB9A (0.71) | RAB9ANPC1LMNAL3MBTL1MAPT | |
| SCHEMBL8956384 | 0.81 | RAB9A (0.71) | RAB9ANPC1PTPN1L3MBTL1MAPT | |
| SCHEMBL6203410 | 0.81 | PTPN1 (0.55) | RAB9ANPC1PTPN1LMNAHTT | |
| SCHEMBL6202445 | 0.81 | RAB9A (0.71) | RAB9ANPC1PTPN1L3MBTL1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260124204-A1 | METALLOENZYME INHIBITOR COMPOUNDS | EIKONIZO THERAPEUTICS, INC. (US) | 2026-05-07 | — | — | US | disclosed |
| US-12370194-B2 | Metalloenzyme inhibitor compounds | EIKONIZO THERAPEUTICS, INC. (US) | 2025-07-29 | — | — | US | disclosed |
| US-20240307391-A1 | METALLOENZYME INHIBITOR COMPOUNDS | EIKONIZO THERAPEUTICS, INC. (US) | 2024-09-19 | — | — | US | disclosed |
| US-11938134-B2 | Metalloenzyme inhibitor compounds | EIKONIZO THERAPEUTICS, INC. (US) | 2024-03-26 | — | — | US | disclosed |
| US-20220088018-A1 | METALLOENZYME INHIBITOR COMPOUNDS | EIKONIZO THERAPEUTICS, INC. (US) | 2022-03-24 | — | — | US | disclosed |
| US-20200171028-A1 | METALLOENZYME INHIBITOR COMPOUNDS | VIAMET PHARMACEUTICALS HOLDINGS, LLC | 2020-06-04 | — | — | US | disclosed |
| US-20200171028-A1 | METALLOENZYME INHIBITOR COMPOUNDS | VIAMET PHARMACEUTICALS HOLDINGS, LLC | 2020-06-04 | — | — | US | disclosed |
| US-10357493-B2 | Metalloenzyme inhibitor compounds | SELENITY THERAPEUTICS (BERMUDA), LTD. (BM) | 2019-07-23 | — | — | US | disclosed |
| US-10357493-B2 | Metalloenzyme inhibitor compounds | SELENITY THERAPEUTICS (BERMUDA), LTD. (BM) | 2019-07-23 | — | — | US | disclosed |
| US-20180256572-A1 | METALLOENZYME INHIBITOR COMPOUNDS | VPS-3, INC. (US) | 2018-09-13 | — | — | US | disclosed |
| US-9884063-B2 | Amido-substituted azole compounds | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-02-06 | — | — | US | disclosed |
| US-20170020886-A1 | AMIDO-SUBSTITUTED AZOLE COMPOUNDS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170020886-A1 | AMIDO-SUBSTITUTED AZOLE COMPOUNDS | TNK1, TNNI3K, TNKS | RAB9A 2695/4885NPC1 2994/4885PTPN1 227/4885 |
| US-20240307391-A1 | METALLOENZYME INHIBITOR COMPOUNDS | HDAC6, HDAC1, HDAC2 | RAB9A 1505/4885NPC1 320/4885PTPN1 3411/4885 |
| US-20220088018-A1 | METALLOENZYME INHIBITOR COMPOUNDS | HDAC6, HDAC1, HDAC2 | RAB9A 1505/4885NPC1 320/4885PTPN1 3411/4885 |
| US-20180256572-A1 | METALLOENZYME INHIBITOR COMPOUNDS | HDAC6, HDAC1, HDAC2 | RAB9A 1505/4885NPC1 320/4885PTPN1 3411/4885 |
| US-20200171028-A1 | METALLOENZYME INHIBITOR COMPOUNDS | HDAC6, HDAC1, HDAC2 | RAB9A 1505/4885NPC1 320/4885PTPN1 3411/4885 |
| US-20260124204-A1 | METALLOENZYME INHIBITOR COMPOUNDS | HDAC6, HDAC3, HDAC1 | RAB9A 340/4885NPC1 710/4885PTPN1 1694/4885 |
| US-11938134-B2 | Metalloenzyme inhibitor compounds | HDAC6, HDAC1, HDAC2 | RAB9A 1505/4885NPC1 320/4885PTPN1 3411/4885 |
| US-10357493-B2 | Metalloenzyme inhibitor compounds | HDAC6, HDAC1, HDAC2 | RAB9A 1505/4885NPC1 320/4885PTPN1 3411/4885 |
| US-12370194-B2 | Metalloenzyme inhibitor compounds | HDAC6, HDAC1, HDAC2 | RAB9A 1505/4885NPC1 320/4885PTPN1 3411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.